We propose that further investigation of these altered CD4 T cell characteristics be evaluated in T2D patients at different stages of TB, and in complement with animal models, to identify pathways in Th17 cell development that favor the generation of protective Th17 cell subsets that can be targets of host-directed therapies for both TB, particularly in patients with T2D. Here, CD4 is linked to type 2 diabetes mellitus.